TSX:ONC 0.37 CAD -0.01 -1.33% Volume: 95,800 November 25, 2015
OTCQX:ONCYF 0.28 USD -0.01 -2.44% Volume: 62,235 November 25, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

November 18, 2015 Oncolytics Biotech® Inc. Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN® in Combination with Bortezomib
November 05, 2015 Oncolytics Biotech® Inc. Announces 2015 Third Quarter Results
October 29, 2015 Oncolytics Biotech® Inc. Announces Receipt of Qualification for Trading on the OTCQX and Nasdaq Notice of Delisting
Sign up to receive e-mail updates *